MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
10.51
-0.39
-3.58%
After Hours: 10.70 +0.19 +1.81% 19:55 12/08 EST
OPEN
10.81
PREV CLOSE
10.90
HIGH
11.18
LOW
10.41
VOLUME
2.63M
TURNOVER
0
52 WEEK HIGH
11.93
52 WEEK LOW
6.08
MARKET CAP
858.39M
P/E (TTM)
-3.8779
1D
5D
1M
3M
1Y
5Y
1 Promising Stock Down 66% That Could Skyrocket in 2024
Editas medicine is a small-cap gene-editing specialist. The company's stock has been rebounding this year. Editas medicine has positive data from a clinical trial for its edit-301 therapy. The company could have a good chance of winning approval in the future.
The Motley Fool · 3d ago
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Gene editing could unlock billions of dollars in latent value for investors. Crispr therapeutics and intellia are among the early leaders in the gene editing field. The field's uncertain future makes gene editing stocks worth owning as a hedge against the field's long-term prospects.
The Motley Fool · 4d ago
Weekly Report: what happened at EDIT last week (1127-1201)?
Weekly Report · 4d ago
Even after rising 6.1% this past week, Editas Medicine (NASDAQ:EDIT) shareholders are still down 66% over the past three years
Editas medicine, inc. (nasdaq:edit) has rebounded 72% in the last month. Over the last three years the share price has dropped 66%. The company has no profits and its revenue has fallen 60% per year. Editas medicine shareholders are up 8.2% for the year, but the stock has fallen 66% in three years. The company's revenue is expected to grow at a slower rate than profits.
Simply Wall St · 11/29 10:40
Weekly Report: what happened at EDIT last week (1120-1124)?
Weekly Report · 11/27 09:12
CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big
Gene editing allows scientists to modify the dna of organisms using biotechnological techniques. Crispr-cas9 is the most widely used gene editing technology. This 2-part series will cover the basics of gene editing and the major players involved in the field. I think it is an important time to learn about the technology.
Seeking Alpha · 11/25 08:39
Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year
NASDAQ · 11/25 00:53
Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year
NASDAQ · 11/23 23:57
More
About EDIT
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cas12a), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of in vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, EDIT-301, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta-thalassemia (TDT).

Webull offers Editas Medicine Inc stock information, including NASDAQ: EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.